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CORRELATION OF LIVER ELASTOGRAPHY WITH LIPID PROFILE, 
LIVER FUNCTION TEST, AND HbA1c IN TYPE II DIABETES IN HOSPITAL 
UNIVERSITI SAINS MALAYSIA 
 
ABSTRACT 
 
Background 
Non-alcoholic fatty liver disease (NAFLD) is a range of liver disorders which ranges 
from simple accumulation of fat in the hepatocytes (steatosis) to macrovescicular 
steatosis, periportal and lobular inflammation (steatohepatitis). The current gold 
standard to diagnose liver diseases is biopsy, however this has two major problems: it is 
dependent on the sampling area, which may cause an evaluation error in the case of 
mild fatty liver, and it is an invasive technique which carries a morbidity rate of 1-5% 
and a mortality rate of 0.01-0.1%. Non-invasive imaging tools such as shear wave 
elastrography has been proven to be useful for screening and categorizing of chronic 
liver disease, however, further evaluation of this tool is needed in different population. 
 
Aim and Objective 
This study aimed to assess the associations among liver elastography, lipid profile, liver 
function test and HbA1c among type II diabetic patient in Hospital Universiti Sains 
Malaysia, in which (i) the prevalence and incidence rate of NAFLD and liver 
fibrosis/cirrhosis among type II diabetic patient in Hospital Universiti Sains Malaysia 
was determined, respectively; (ii) the mean values of the blood lipid profile, liver 
functions test and HBA1c among patient with and without NAFLD were compared; and 
 x 
 
(iii) the associations between degree of liver elasticity; and blood lipid profil, liver 
function test and HBA1c were investigated. 
 
Method 
Patients were recruited from Diabetic Clinic, HUSM. Only patients who fulfilled the 
selection criteria and provided written consent were enrolled into this study. The 
Medical record of the patient was provided by the clinic. Liver elastrography was 
performed in Radiology Department, HUSM by Supersonic Imagine Using Shear Wave 
Elastography (Siemens Acuson Antares -Premium Edition, Camberley, UK), equipped 
with Aixplorer Multiwave. Data were recorded and analysed using SPSS version 22.0. 
 
Result 
The prevalence of NAFLD among participant with DM type II was 87%, while the 
incidence rate of liver fibrosis among the patients with NAFLD was 11.7% (8/68). The 
distribution of METAVIR score among T2DM patients were F0 (60/68), F1 (7/68), and 
F2 (1/68). The result revealed very poor correlation between SWE values and part of the 
study parameters, which includes HDL, LDL, TG, AST and HbA1c (P>0.05). However, 
there were two parameters showed significant weak association between SWE values; 
TC (r=0.283; P=0.019) and ALT (r=0.252; P=0.038). 
 
Conclusion 
This study had determined to the prevalence of NAFLD and incidence rate of liver 
fibrosis among T2DM patients admitted to HUSM. The prevalence of NAFLD was 
higher but the incidence rate of liver fibrosis was lower compared to previous study. 
 xi 
 
Further research with inclusion of parameters like race, AST/ALT ratio and advanced 
fibrosis patients to strengthen the finding of current conclusion.  
 xii 
 
KORELASI ANTARA ELASTOGRAPHY HATI DENGAN PROFIL LIPID, 
UJIAN FUNGSI HATI, DAN HbA1c DALAM KALANGAN PESAKIT 
DIABETES JENIS II DI HOSPITAL UNIVERSITI SAINS MALAYSIA 
 
 
ABSTRAK 
 
Latar Belakang 
Penyakit perlemakan hati bukan alcohol (NAFLD) adalah penyakit gangguan hati yang 
luas spectrum, bermula dari pengumpulan lemak dalam hepatosit (steatosis) sehingga 
menjadi steatosis macrovaskular, keradangan periportal dan seterusnya lobular 
(steatohepatitis). Standard diagnosis semasa untuk NAFLD ialah biopsi. Namun cara ini 
mempunyai dua kelemahan utama: (i) ia bergantung kepada kawasan persampelan, yang 
mungkin menyebabkan kesilapan penilaian dalam kes hati berlemak ringan, dan (ii) ia 
adalah satu teknik invasif yang mungkin membawa kepada kadar morbiditi 1-5% dan 
kadar kematian sebanyak 0,01-0,1%. Alat pengimejan tidak invasif seperti shear wave 
elastrography telah terbukti berguna untuk pemeriksaan dan mengkategorikan tahap 
penyakit hati kronik, bagaimanapun, penilaian lanjut alat ini diperlukan dalam populasi 
yang berbeza. 
 
Matlamat dan Objektif 
Kajian ini bertujuan untuk menilai perkaitan antara elastografi hati, profil lipid, ujian 
fungsi hati dan paras gula puasa dalam darah di kalangan pesakit kencing manis jenis II 
(T2DM) di Hospital Universiti Sains Malaysia, di mana (i) prevalens NAFLD dan kadar 
insiden cystic hati / sirosis di kalangan T2DM di Hospital Universiti Sains Malaysia 
 xiii 
 
telah ditentukan; (ii) nilai min profil lipid darah, fungsi hati dan ujian HbA1c di 
kalangan pesakit dengan dan tanpa NAFLD dibandingkan; dan (iii) perkaitan antara 
tahap keanjalan hati; dan profil lipid darah, ujian fungsi hati dan HbA1c telah disiasat. 
 
Kaedah 
Pesakit telah dipilih dari Klinik Diabetik, HUSM. Hanya pesakit yang memenuhi 
kriteria pemilihan dan memberi persetujuan bertulis akan dipelawa untuk kajian ini. 
Rekod perubatan pesakit telah disediakan oleh klinik. Elastrografi hati telah dilakukan 
di Jabatan Radiologi, HUSM dengan menggunakan Supersonic Imagine Using Shear 
Wave Elastography (Siemens Acuson Antares -Premium Edition, Camberley, UK), 
equipped Aixplorer Multiwave. Data telah direkodkan dan dianalisis dengan 
menggunakan SPSS. 
 
Keputusan 
Prevalens NAFLD antara pesakit T2DM adalah 87% (68/78), manakala kadar insiden 
cystic hati / sirosis di kalangan pesakit NAFLD adalah 11.7% (8/68). Skor METAVIR 
pesakit-pesakit T2DM adalah F0 (60/68), F1 (7/68), dan F2 (1/68). Hasil kajian ini 
mendedahkan yang hubungan yang sangat lemah dan tidak ketara (P> 0.05) antara nilai-
nilai SWE dengan sebahagian daripada parameter-parameter kajian, termasuk HDL, 
LDL, TG, AST dan HbA1c. Walau bagaimanapun, terdapat dua parameter 
menunjukkan perkaitan lemah yang ketara dengan nilai-nilai min SWE; TC (r = 0,283; 
P = 0.019) dan ALT (r = 0,252; P = 0.038). 
 
Kesimpulan 
 xiv 
 
Kajian ini telah menentukan prevalans NAFLD dan kadar insidens cystic hati / sirosis di 
kalangan pesakit T2DM di HUSM. Prevalens NAFLD adalah lebih tinggi berbanding 
dengan kajian lepas. Namun, kadar insiden cystic hati / sirosis adalah lebih rendah. 
Kajian seterusnya dengan pertimbangan unsur-unsur seperti etnik, nisbah AST/ALT dan 
pesakit fibrosis serius harus dikaji untuk memperkukuhkan hasil kajian sekarang. 
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Introduction: Non-alcoholic fatty liver disease (NAFLD) is a range of liver disorders which 
ranges from simple accumulation of fat in the hepatocytes (steatosis) to macrovescicular steatosis, 
periportal and lobular inflammation (steatohepatitis). The current gold standard to diagnose liver 
diseases is biopsy, however this has two major problems: it is dependent on the sampling area, 
which may cause an evaluation error in the case of mild fatty liver, and it is an invasive 
technique which carries a morbidity rate of 1-5% and a mortality rate of 0.01-0.1%. Non-
invasive imaging tools such as shear wave elastrography has been proven to be useful for 
screening and categorizing of chronic liver disease, however, further evaluation of this tool is 
needed in different population. 
 
Objective: This study aimed to assess the associations among liver elastography, lipid profile, 
liver function test and HbA1c among type II diabetic patient in Hospital Universiti Sains 
Malaysia, in which (i) the prevalence and incidence rate of NAFLD and liver fibrosis/cirrhosis 
among type II diabetic patient in Hospital Universiti Sains Malaysia was determined, 
respectively; (ii) the mean values of the blood lipid profile, liver functions test and HBA1c 
among patient with and without NAFLD were compared; and (iii) the associations between 
degree of liver elasticity; and blood lipid profil, liver function test and HBA1c were investigated. 
 
Patients and Methods: Patients were recruited from Diabetic Clinic, HUSM. Only patients who 
fulfilled the selection criteria and provided written consent were enrolled into this study. The 
Medical record of the patient was provided by the clinic. Liver elastrography was performed in 
Radiology Department, HUSM by Supersonic Imagine Using Shear Wave Elastography 
(Siemens Acuson Antares -Premium Edition, Camberley, UK), equipped with Aixplorer 
Multiwave. Data were recorded and analysed using SPSS version 22.0. 
 
Results: The prevalence of NAFLD among participant with DM type II was 87%, while the 
incidence rate of liver fibrosis among the patients with NAFLD was 11.7% (8/68). The 
distribution of METAVIR score among T2DM patients were F0 (60/68), F1 (7/68), and F2 
(1/68). The result revealed very poor correlation between SWE values and part of the study 
parameters, which includes HDL, LDL, TG, AST and HbA1c (P>0.05). However, there were 
two parameters showed significant weak association between SWE values; TC (r=0.283; 
P=0.019) and ALT (r=0.252; P=0.038). 
 
Conclusion: This study had determined to the prevalence of NAFLD and incidence rate of liver 
fibrosis among T2DM patients admitted to HUSM. The prevalence of NAFLD was higher but 
the incidence rate of liver fibrosis was lower compared to previous study. Further research with 
inclusion of parameters like race, AST/ALT ratio and advanced fibrosis patients to strengthen the 
finding of current conclusion. 
  
 
 
 
 
SECTION ONE 
INTRODUCTION 
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CHAPTER 1 
INTRODUCTION 
 
1.1  Background of the Study 
In developing country such as Malaysia, metabolic syndrome such as NAFLD and DM 
has become major health problem in our community due to our sedentary life style and 
bad eating habits. NAFLD and T2DM are co-exist because they share the common risk 
factors (Macabuag-Oliva et al., 2014). Obesity, insulin resistance and increased plasma 
fatty acid concentrations are considered to increase the risk of fatty liver, which are also 
the characteristic of T2DM. The incidence of NAFLD and fibrosis progression, 
including hepatocellular carcinoma, has been found to be significantly higher in diabetic 
patients compared with non-diabetic patients.  
 
Paralleling the increasing prevalence of obesity, diabetes mellitus, and the 
metabolic syndrome in the general population, nonalcoholic fatty liver disease (NAFLD) 
has become the most common cause of chronic liver disease worldwide (Browning et 
al., 2004). NAFLD refers to the accumulation of hepatic steatosis, independent of 
excess alcohol consumption and its effects on the liver. It is  a broad continuum of liver 
illnesses extending from the rather benign steatosis to the severe cryptogenic cirrhosis. 
Steatosis, or fatty infiltration of the liver, can progress to nonalcoholic steatohepatitis 
(NASH). Steatohepatitis, in turn, can progress to permanent liver damage in the form of 
cirrhosis or malignancy; 3% to 5% of patients with NAFLD progress to NASH, and 
15% of those with NASH develop cirrhosis (Levinthal and Tavill, 1999; Smith and 
Adams, 2011) 
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Within the spectrum of NAFLD, simple bland steatosis often remains stable for 
a number of years and will probably never progress in many patients (Teli et al., 1995; 
Dam-Larsen et al., 2004). A subset of patients, however, particularly those with more 
advanced fibrosis, are at a higher risk for progressing to decompensated cirrhosis, portal 
hypertension, HCC, or death if liver transplantation is not accomplished (Dam-Larsen et 
al., 2004; Ekstedt et al., 2006). In contrast to patients with bland steatosis, patients with 
increased liver fibrosis require close follow-up with surveillance for the development of 
esophageal varices and HCC and enrollment into treatment trials. Thus, identifying the 
presence and severity of liver fibrosis in patients with NAFLD is of major importance in 
guiding the subsequent management of patients with this liver condition.  
 
The life span of human population in developed and developing countries has 
increased due to the improvement of health and welfare policy. Aging markedly 
increases the prevalence of the metabolic syndrome in the human population (Ford et al., 
2002). Accumulating evidence also points toward an increased prevalence of NAFLD 
with older age in humans (Floreani, 2007). Sheedfar et al. (2013) has described the 
association between NAFLD and aging. This disease has a trend that increase with 
aging process, but significantly reduced in very elderly population, as illustrated in 
Figure 1.1. Although it is much debated whether insulin resistance is a cause of age-
associated metabolic disturbances or rather a protective adaptive mechanism (Barzilai 
and Ferrucci, 2012). It is generally believed that age is a risk factor for increased hepatic 
steatosis. Fat may accumulate in the liver as a result of multiple abnormalities of hepatic 
lipid metabolism, although the mechanisms that underlie this age-related liver steatosis 
are yet to be clearly defined. These mechanisms may include enhanced fat uptake, 
increased de novo lipogenesis, decreased β-oxidation, and/or decreased 
synthesis/secretion of very low-density lipoproteins (Cohen et al., 2011). 
 3 
 
 
 
Note: The incidence of liver diseases in humans increases with age up to 75 years. Interestingly, 
subjects aged more than 75 have a significantly reduced incidence of HCC (left). The different 
states of liver disease progression (NAFLD, NASH, cirrhosis and HCC) and the respective 
molecular changes are represented on the right. Adopted from Sheedfar et al. (2013). 
Figure 1.1 Schematic illustration of the pattern of liver disease progression during 
aging 
  
The prevalence of NAFLD is up to 30% in developed countries and nearly 10% 
in developing nations, making NAFLD the most common liver condition in the world. 
One in 3 adult Americans and 1 in 4 or 5 adult Italians suffer from NAFLD (Browning 
et al., 2004; Bedogni et al., 2005). NAFLD also has reached epidemic proportions 
among populations typically considered at low risk, with a prevalence of 15% in China 
and 14% in Japan (Nomura et al., 1988; Fan et al., 2005). The underlying relationship 
between NAFLD and DM is still under discovery, and pharmacogenetic factor might be 
considered as the contributing factor, suggested by Firneisz (2014). 
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In the absence of decompensated cirrhosis, liver biopsy remains the only reliable 
means to determine prognosis based on the severity of fibrosis. However, liver biopsy is 
an expensive and invasive procedure associated with a number of complications and 
prone to sampling error. Because of all this, efforts have been made to identify 
noninvasive indicators of liver fibrosis in patients with NAFLD. Noninvasive 
approaches for assessing the severity of fibrosis in NAFLD have included a 
combination of clinical features and routine laboratory investigations as well as some 
less readily available serum markers of fibrosis (Angulo et al., 1999; Dixon et al., 2001; 
Rosenberg et al., 2004). These noninvasive approaches are, however, either 
insufficiently accurate in their prediction of liver fibrosis or their diagnostic accuracy 
has been evaluated in only a limited number of patients with NAFLD; further, most 
have not been validated in a separate population of NAFLD patients (Angulo et al., 
1999). 
 
This study utilized SWE for screening of NAFLD among targeted population 
which is T2DM patient. Significant and useful finding were found from these analysis, 
as the authors found high correlation between SWE reading and the conventional 
METAVIR, the liver fibrosis scaling system. SWE cut-off value for METAVIR scoring 
system was established and can be used to categorize liver fibrosis status of a patient 
(Ferraioli et al., 2014a). It is easy and produced fast result as compared to the gold 
standard, liver biopsy. This could improve the management of NAFLD as well as other 
chronic liver in HUSM. By the way, all noninvasive methods are ready to be used for 
detecting and staging liver fibrosis before therapy at a safe level of predictability. As 
with transient elastography, elastographic techniques based on shear waves generated 
by the acoustic beam are more accurate in detecting cirrhosis than significant fibrosis. 
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They have the advantage of B-mode guidance, which allows one to choose an area of 
liver parenchyma better suited for stiffness assessment (i.e. free of large vessels and 
focal lesions). Nevertheless, these methods are all valid when information about fibrosis 
is needed. Liver biopsy should still be performed when biochemical tests and imaging 
studies are inconclusive or information other than liver fibrosis is required (Ferraioli et 
al., 2014a; Ferraioli et al., 2014b). 
 
1.2  Rationale of the Study 
NAFLD has been reported among hypercholesterolaemic patient is Hospital Universiti 
Sains Malaysia with the incident rate of 56.7%. The NAFLD was defined by using 
visual scoring system using high sensitivity B-mode ultrasound, Pentax-Hitachi 
EUB6500 (Tokyo, Japan). Two experienced radiologists were blinded to the clinical 
and metabolic conditions of the subjects. The US evaluation consisted of a visual 
scoring system which assigned to focal hyperechoic hepatic areas of interest a value 
between 0 and 2. Hepatorenal echodiscrepancy, posterior echo penetration and portal 
vein wall clarity were the zones where echogenicity were evaluated. A total score >3 
was interpreted as having a fatty liver, with grade 3 being mild, 4 moderate and 5-6 
severe. The subjects were examined in the supine position. Anyhow, the data on the 
type II diabetic patients is still under-report (Magosso et al., 2010). The incident of liver 
fibrosis and cirrhosis were also not reported. This is probably due to the conventional 
invasive liver biopsy for analysing of the degree of liver fibrosis progression. 
Shearwave elastography has been introduced for detection and grading of liver fibrosis 
and cirrhosis. This is a non-invasive technique for analysis of liver stiffness which 
offers easier clinical management for detection of NAFLD as compared to conventional 
liver biopsy. Thus far, this non-invasive technique was not applied for routine screening 
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purposes due to lack of supporting study of its usefulness in local population. In this 
study we would like to assess the correlation of liver elastography with lipid profile, 
liver function and HbA1c in T2DM patient in Hospital Universiti Sains Malaysia 
(HUSM). This information will provide preliminary data on prevalence of NAFLD and 
liver cirrhosis/fibrosis using elastography among the T2DM patient in HUSM using 
SWE method, and to look for its correlation with parameters that might affect the 
disease. These data might help to support the establishment of SWE method for routine 
liver fibrosis screening.  
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LITERATURE REVIEW 
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CHAPTER 2 
LITERATURE RIVIEW 
 
2.1  Diabetic Mellitus 
Diabetes is an incurable chronic disease. It is a metabolic disorder in which the body 
unable to produce or produce too little or unable to properly use insulin, a hormone that 
is important in sugar metabolism. In diabetic patient, the body is unable to properly 
store and use the energy found in food. Human body cells need sugar as fuel for cell 
metabolism. Sugar or glucose cannot pass through cells directly. When blood sugar 
rises, beta cells in the pancreas secrete insulin. Insulin binds to cells and trigger the 
absorption of blood sugar; the blood sugar level in bloodstream decrease. Thus, insulin 
is generally known as the key factor that signal blood sugar absorption by body cells 
and be used for cell metabolism. The cause of diabetic is still under controversy. 
Genetics and environment factors is the two major contributing factors to this metabolic 
syndrome (Malaysian-Diabetes-Association, 2013). Generally, diabetes is divided into 
two categories, namely Type I or Type II diabetes. 
 
2.2  Diabetes in Malaysia 
According to International-Diabetes-Federation (2015), Malaysia is one of the 23 
countries and territories of the IDF West Pacific region. There were 387 million people 
have diabetes in the world and almost 138 million people in the West Pacific region; by 
2035 this will rise to 202 million. There were 3.2 million cases of diabetes in Malaysia 
in 2014. The prevalence of diabetes is increasing at 0.2% per year according to 
Ministry-of-Health-Malaysia (2010). 
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2.3  Types of Diabetes and Complications 
Type I diabetes is also known as insulin-dependent diabetes mellitus. This disease is 
usually onset at child or young adult stage. It is also call juvenile-onset diabetes. This 
metabolic disorder onset when the body ceases to produce or produce too little insulin. 
Type II diabetes is also known as non-insulin-dependent diabetes mellitus. This disease 
is usually presented as maturity-onset diabetes, as most of the individuals who get this 
disease are over 40 years old. This is the most common diabetes, with the ratio os 10:1 
with type I diabetes. In type II diabetes individuals, human body does not make 
sufficient insulin or human body could not use the insulin been produced (UMMC, 
2015). Patients with diabetes have higher death rates than people who do not have 
diabetes regardless of sex, age, or other factors (UMMC, 2015). Heart disease and 
stroke are the leading causes of death in these patients. People with type 2 diabetes are 
also at risk for nerve damage (neuropathy) and abnormalities in both small and large 
blood vessels (vascular injuries) that occur as part of the diabetic disease process. Such 
abnormalities produce complications over time in many organs and structures in the 
body, e.g. kidney, foot, eyes, etc. Diabetes also increases the risk for developing other 
conditions, including: 
• Hearing loss 
• Periodontal disease 
• Carpal tunnel syndrome 
• Nonalcoholic fatty liver disease (NAFLD), also called nonalcoholic 
steatohepatitis (NASH), a particular danger for people who are obese 
• Cancers of the liver, pancreas, and endometrium and, to a lesser extent, colon 
and rectum, breast, and bladder 
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2.4  Liver and Type II Diabetic Mellitus 
According to Levinthal and Tavill (1999), the liver plays an important role in regulation 
of carbohydrate homeostasis. It is important to understand the alteration and changes in 
physical and biochemical component of liver in diabetes. The liver uses glucose as a 
fuel and also has the ability to store it as glycogen and synthesize it from non-
carbohydrate precursors (gluconeogenesis). Glucose absorbed from the intestinal tract is 
transported via the portal vein to the liver. Although the absolute fate of this glucose is 
still controversial, some authors suggest that most of the absorbed glucose is retained by 
the liver so that the rise in peripheral glucose concentration reflects only a minor 
component of postprandial absorbed glucose. Diabetes mellitus is known to cause many 
complications to the liver such as glycogen deposition, fatty liver, and cirrhosis. Excess 
glycogen accumulation in the liver is seen in 80% of diabetic patients. Glycogen 
synthesis in the liver is impaired in diabetes due to defective activation of glycogen 
synthase. Almost 40 to 70% of diabetes patient have hepatic fat accumulation. Type 2 
diabetes mellitus is strongly associated with fat accumulation regardless the glucose 
control. Fat is stored in the form of triglyceride and may be a manifestation of increased 
fat transport to the liver, enhanced hepatic fat synthesis, and decreased oxidation or 
removal of fat from the liver. Diabetes mellitus is also known to increase the risk of 
steatohepatitis  subsequently leading to cirrhosis. The prevalence of Type 2 diabetes is 
expected to increase in parallel with obesity rates and the ageing population. Recent 
studies show that Type 2 diabetes is associated with a twofold increase in the risk of 
non-alcoholic fatty liver disease, a leading cause of chronic liver disease (Tai et al., 
2015). Individuals with non-alcoholic steatohepatitis, a more advanced stage of non-
alcoholic fatty liver disease, are specifically at risk of developing fibrosis/cirrhosis (end-
stage liver disease) and hepatocellular carcinoma; therefore, identifying individuals 
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(with Type 2 diabetes) who are likely to develop hepatic complications is paramount 
(Tai et al., 2015). 
 
2.5  Non-Alcoholic Fatty Liver Disease 
Parallel with increase in obesity, there is an increase in obesity-associated diseases such 
as type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). 
NAFLD has become the most common cause of liver disease worldwide. Non-alcoholic 
fatty liver disease (NAFLD) encompasses a spectrum of pathological conditions. The 
early stage of NAFLD starts with lipid accumulation in the liver also known as hepatic 
steatosis in the absence of excessive alcohol consumption (typically a threshold of 20 
g/d for women and 30 g/d for men is adopted). This benign and reversible state of 
NAFLD may, however, evolve into non-alcoholic steatohepatitis (NASH), a condition 
of inflamed liver, which can further progress to liver fibrosis, cirrhosis and ultimately 
hepatocellular carcinoma (Ahmed et al., 2010; Ratziu et al., 2010; Anstee et al., 2011). 
NAFLD has emerged as a growing public health problem worldwide that has reached 
epidemic proportions and is the most common cause of chronic liver disease in many 
developed countries. NAFLD increases the risk of end-stage liver disease, and NAFLD-
induced liver failure is one of the most important reasons for liver transplantation. 
NAFLD is also strongly associated with overweight/obesity, insulin resistance, and type 
2 diabetes (T2DM) (Ahmed et al., 2010; Ratziu et al., 2010; Anstee et al., 2011). 
NAFLD is a manifestation of pathological ectopic fat accumulation combined with a 
low-grade chronic inflammatory state in an organ that is not able to accumulate fat. This 
condition is still poorly recognized by endocrinologists and general physicians, and 
recent work is now suggesting putative mechanisms by which NAFLD not only 
increases risk of developing T2DM, but also worsens glycemic control and contributes 
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to the pathogenesis of major chronic complications of diabetes, such as cardiovascular 
disease (CVD) and chronic kidney disease (CKD), in people with established T2DM.  
 
2.6  Diagnosis of NAFLD 
2.6.1 Liver biopsy 
The diagnosis of chronic liver disease is often made from needle biopsy samples. Liver 
biopsy and histological analysis are considered the diagnostic reference standard for the 
assessment of fatty liver. Histological assessment provides information about the fat 
distribution within the hepatic lobules and allows for a semi-quantitative evaluation of 
steatosis (Joseph et al., 1991; Chitturi et al., 2007). Microscopically, the steatosis 
pattern can be divided into macro- and micro-vesicular steatosis with hepatocytes 
containing either one large vacuole of fat which is larger than the hepatocyte nucleus 
and displaces the nucleus or many small fatty cytoplasmatic inclusions without a 
significant nuclear displacement Macro-vesicular steatosis is more common and is 
found in NAFLD but also in alcoholic fatty liver disease (Oleszczuk et al., 2007). In 
contrast, micro-vesicular steatosis is generally a more severe form of steatosis and is 
seen in a variety of conditions such as toxicity of several medications, defect in beta-
oxidation of fatty acids, Reye’s syndrome but also in alcoholism.  
 
In addition to establishing a disease etiology, liver biopsy can determine the 
degree of inflammation present and can stage the degree of fibrosis. The degree of 
inflammation and fibrosis may be assessed by different scoring schemes. Histological 
(biopsy) diagnosis classifies the severity of fibrosis into five stages, S0 to S4. S0 means 
no fibrosis. S4 is cirrhosis. In between, S1 is a mild fibrosis only seen at the portal area. 
S2 is a moderate stage of fibrosis, between portal areas, but without the destruction of 
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the lobular structure. S3 is severe fibrosis. At this stage, there is fibrostic bridging 
between portal areas and between portal areas and center veins. At S4, in addition to 
S3's changes, there are pseudo-lobules formed and this stage is the final stage, cirrhosis.  
 
The METAVIR score is an established method helps pathologist to interpret a 
liver biopsy (Kaplan and Bonis, 2009). When this biopsy is performed, clinician needs a 
reliable way to quantify what is seen under the microscope. This scoring system assigns 
two standardized numbers: one to represent the degree of inflammation and the other 
the degree of fibrosis. The activity, which is the amount of inflammation (specifically, 
the intensity of necro-inflammatory lesions), is graded on a 4-point scale from A0 to A3. 
Fibrosis score: 
• F0 = no fibrosis 
• F1 = portal fibrosis without septa 
• F2 = portal fibrosis with few septa 
• F3 = numerous septa without cirrhosis 
• F4 = cirrhosis 
Activity score: 
• A0 = no activity 
• A1 = mild activity 
• A2 = moderate activity 
• A3 = severe activity 
There are several limitations to liver biopsy, including its invasive nature, small 
tissue sample size, and subjective grading system. Regarding small tissue sample size, 
liver fibrosis can be patchy and thus missed on a biopsy sample, which includes only 
0.002% of the liver tissue (Bedossa et al., 2003; Colloredo et al., 2003; Schiano et al., 
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2005; Chitturi et al., 2007). A noninvasive alternative to liver biopsy would be 
particularly helpful, both to initially assess patients and then as a monitoring tool to 
assess response to therapy (Schwenzer et al., 2009). 
 
2.6.2 Non-Invasive Method 
2.6.2 1 Multi-analyte Assays 
A variety of non-invasive laboratory tests are being evaluated as an alternative to liver 
biopsy. The rapid development of new medications for the treatment of some liver 
diseases, such as CHB, CHC, and nonalcoholic fatty liver disease (NAFLD), increases 
the requirement for more frequent evaluation of liver fibrosis to assess treatment 
response. Liver biopsies are not ideal for frequent evaluations (Fallatah, 2014). The 
typical mechanism underlying the development of hepatic fibrosis is an imbalance 
between the deposition and removal of extracellular matrix (ECM). Hepatic stellate 
cells are the predominant producers of ECM, and their activation and proliferation are 
mediated by different cytokines during the process of liver injury. The activation and 
proliferation of Hepatic stellate cells ultimately result in an excessive deposition of 
ECM. In advanced fibrosis, the ECM may increase sixfold compared with that in 
normal liver. 
 
Biochemical tests can be broadly categorized into indirect and direct markers of 
liver fibrosis. The direct markers directly correlate with or are parts of the liver matrix 
produced by the Hepatic stellate cells during ECM turnover in the fibrosis process. 
Direct markers linked to matrix deposition include Procollagen type 1 and type III; 
Type IV collagen; Hyaluronic acid and Laminin. Direct markers linked to matrix 
degradation include MMP-1 (collagenases), MMP-2 (gelatinase-A), MMP-9 
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(gelatinase-B), and Tissue inhibitors of matrix metalloproteinases (TIMPs). Cytokines 
and chemokines linked to liver fibrosis include transforming growth factor-β (TGF-β1) 
and transforming growth factor alpha (TGF-α). Indirect markers include liver function 
tests such as ALT (alanine aminotransferase) as described by Sebastiani and Alberti 
(2006), AST (aspartate aminotransferase), the ALT/AST ratio, also referred to as the 
AAR proposed by McPherson et al. (2010), AST/platelet ratio (APRI) proposed by Wai 
et al. (2003), The Forns Index (Forns et al., 2002), The PGA Index (CHAPUT, 1991), 
fibro test and fibrosure (Baranova et al., 2011). The first three markers were frequently 
used for prediction of NAFLD, while the latter were commonly applied for prediction 
of alcoholic liver fibrosis. Besides serum markers, lipid profile such as HDL, LDL, TG 
and TC had found to be altered among individuals with NAFLD (Mahaling et al., 
2013). 
 
2.6.2 2 Imaging Technologies 
Non-invasive imaging technologies to detect liver fibrosis or cirrhosis among patients 
with chronic liver disease are also being evaluated as an alternative to liver biopsy. The 
noninvasive imaging technologies include Shear Wave Elastrography (SWE), transient 
elastography (eg, FibroScan®), magnetic resonance elastography (MRE), ARFI (eg, 
Acuson S2000™), and real-time tissue elastography (RTE; eg, HI VISION Preirus). 
Noninvasive imaging tests have been used in combination with multianalyte serum tests 
such as FibroTest or FibroSURE with FibroScan. Liver elasticity is the measurement of 
tissue stiffness in liver is related to tissue composition, which is changed by cirrhosis, 
hepatocellular carcinoma, or metastasis. 
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2.6.2.2.1 Ultrasound 
In ultrasound (US) images, hepatic steatosis appears as a diffuse increase in 
echogenicity due to the increased parenchymal reflectivity caused by intracellular 
accumulation of fat inclusions. Ultrasound is accepted as an initial screening for fatty 
liver since it is non-invasive, inexpensive and widely available (Saverymuttu et al., 
1986; Ricci et al., 1997; Palmentieri et al., 2006; Roldan-Valadez et al., 2008). 
Nevertheless, the sensitivity and specificity of ultrasound in detecting hepatic steatosis 
are a constant matter of debate. The previous studies demonstrated that ultrasonography 
has a sensitivity of 60–94% and a specificity of 66–95% in detecting fatty liver (Foster 
et al., 1980; Debongnie et al., 1981; Steinmaurer et al., 1984; Saverymuttu et al., 1986; 
Graif et al., 2000). In most studies, liver biopsy was used as the gold standard. The 
specificity could be increased up to 100% if known liver disease, drug use or alcohol 
consumption were ruled out (Hamaguchi et al., 2007). Several studies demonstrated that 
ultrasound cannot reliably distinguish between fibrosis and steatosis (Taylor et al., 
1981; Meek et al., 1984). Others concluded that it is possible to differentiate between 
fibrosis and hepatic steatosis, at least at higher degrees of fibrosis leading to an increase 
in coarse echoes without posterior beam attenuation (Saverymuttu et al., 1986; 
Palmentieri et al., 2006). Although ultrasound has been shown to have an acceptable 
level of sensitivity it does not provide reproducible quantitative information. 
 
2.6.2.2.1 (i) B-mode 
In B-mode (brightness mode) ultrasound, a linear array of transducers simultaneously 
scans a plane through the body that can be viewed as a two-dimensional image on 
screen. It is commonly known as 2D mode. Toyoda et al. (2009) had performed a study 
on liver fibrosis using B-mode ultrasound with algorithm based on statistical analysis of 
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signals. The result revealed the grades of liver fibrosis in patients with chronic hepatitis 
C are well discriminated with the B-mode ultrasound–based analysis algorithm without 
discrimination between grades F0 and F1. This showed that findings on conventional 
ultrasound images may reflect progression of liver fibrosis even in the absence of 
cirrhosis. 
 
2.6.2.2.1 (ii) Transient Elastography 
Transient elastography (FibroScan®) uses a mechanical vibrator to produce mild 
amplitude and low-frequency (50 Hz) waves, inducing an elastic shear wave that 
propagates throughout the liver. US tracks the wave, measuring its speed, which 
correlates with liver stiffness. Increases in liver fibrosis also increase liver stiffness and 
resistance of liver blood flow. Transient elastography does not perform as well in 
patients with ascites, higher body mass index, or narrow intercostal margins. Although 
FibroScan may be used to measure fibrosis, unlike liver biopsy, it does not provide 
information on necroinflammatory activity and steatosis, nor is it accurate during acute 
hepatitis or hepatitis exacerbations. 
 
2.6.2.2.1 (iii) Shear Wave Elastrography 
It is a non-invasive technique to asses liver tissues stiffness. The principle of SWE was 
as shown in Figure 2.1. Shear wave elastography relies on the generation of shear waves 
determined by the displacement of tissues induced by the force of a focused ultrasound 
beam or by external pressure. The shear waves are lateral waves, with a motion 
perpendicular to the direction of the force that has generated them. They travel slowly 
(between 1 and 10 m/s) and are rapidly attenuated by tissue. The propagation velocity of 
the shear waves correlates with the elasticity of tissue; ie, it increases with increasing 
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stiffness of the liver parenchyma. Many studies (Arda et al., 2013; Leung et al., 2013; 
Deffieux et al., 2014; Ferraioli et al., 2014a; Ferraioli et al., 2014b; Suh et al., 2014) 
had correlate SWE values with the METAVIR liver fibrosis score, i.e. F0 (Figure 2.2), 
F1 (Figure 2.3), F2 (Figure 2.4), F3 (Figure 2.5), and F4 (Figure 2.6). These study 
showed promising correlation between SWE and liver fibrosis score, and it is highly 
reproducible. 
 
 
Figure 2.1 Schematic image showing physical principles of ultrasonographic shear 
wave elastography (Arda et al., 2013) 
Note: Transmission of longitudinal acoustic pulse leads to tissue displacement, which 
results in propagation of shear waves away from region of interest (ROI) with 
ultrasound. 
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METAVIR Score F0 
 
Figure 2.2 SWE imaging on subjects liver with METAVIR Score F0 
  
B-Mode only: 
• Good acoustic window even with lateral shadow 
• Vessel free area 
SWE™Mode: 
• SWE box fully filled 
• Homogeneous blue 
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METAVIR Score F1 
 
 
Figure 2.3 SWE imaging on subjects liver with METAVIR Score F1 
 
  
B-Mode only: 
• Good acoustic window even with lateral shadow 
• Vessel free area 
SWE™Mode: 
• SWE box fully filled 
• Homogeneous blue 
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METAVIR Score F2 
 
 
Figure 2.4 SWE imaging on subjects liver with METAVIR Score F2 
  
B-Mode only: 
• Good acoustic window even with lateral shadow 
• Vessel free area 
SWE™Mode: 
• SWE box too close to the capsule (red superficial area) 
• Q-box well positioned in the reasonably homogeneous area 
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METAVIR Score F3 
 
 
Figure 2.5 SWE imaging on subjects liver with METAVIR Score F3 
  
B-Mode only: 
• Good acoustic window even with lateral shadow 
• Vessel free area 
SWE™Mode: 
• SWE box fully filled 
• Hues of blue 
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METAVIR Score F4 
 
Figure 2.6 SWE imaging on subjects liver with METAVIR Score F4 
  
B-Mode only: 
• Good acoustic window even with lateral shadow 
• Vessel free area 
SWE™Mode: 
• A small vessel at the bottom left 
• Q-box well positioned outside the vessel zone 
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2.6.2.2.1 (iv) Acoustic Radiation Force Impulse Imaging 
ARFI uses an US probe to produce an acoustic “push” pulse, which generates shear 
waves that propagate in tissue to assess liver stiffness. ARFI elastography evaluates the 
wave propagation speed to assess liver stiffness. The faster the shear wave speed, the 
harder the object. ARFI technologies include Virtual Touch™ Quantification and 
Siemens Acuson S2000™ system. ARFI elastography can be performed at the same 
time as a liver sonographic evaluation, even in patients with a significant amount of 
ascites. 
 
2.6.2.2.1 (v) Real-Time Elastography 
Real-time elastography is an imaging technique that directly reveals the physical 
property of tissues using conventional US probes (Paparo et al., 2014). RTE is a type of 
strain elastography which uses a combined autocorrelation method to measure tissue 
strain caused by manual compression or a person’s heartbeat. The relative tissue strain 
is displayed on conventional color B mode US images in real time. Hitachi 
manufacturers the RTE devices, including one called HI VISION Preirus. The challenge 
is to identify a region of interest while avoiding areas likely to introduce artifacts, such 
as large blood vessels, the area near the ribs, and the surface of the liver. Areas of low 
strain increase as fibrosis progresses and strain distribution becomes more complex. 
Various subjective and quantitative methods have been developed to evaluate the results. 
RTE can be performed in patients with ascites or inflammation. This technology does 
not perform as well in severely obese individuals. 
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2.6.2.2.2 Magnetic Resonance Elastography 
Magnetic Resonance Elastography (MRE) is a non-invasive MRI based technique for 
quantitatively assessing the mechanical properties of tissues in vivo (Venkatesh et al., 
2013). MRE is performed by using a vibration source to generate low frequency 
mechanical waves in tissue, imaging the propagating waves using a phase contrast MRI 
technique, and then processing the wave information to generate quantitative images 
showing mechanical properties such as tissue stiffness.MRE uses a driver to generate 
60-Hz mechanical waves on the patient’s chest well. The MRI equipment creates 
elastograms by processing the acquired images of propagating shear waves in the liver 
using an inversion algorithm. These elastograms represent the shear stiffness as a pixel 
value in kilopascals. MRE has several advantages over US elastography, including: (1) 
analyzing larger liver volumes; (2) analyzing liver volumes of obese patients or patients 
with ascites; and (3) precise analysis of viscoelasticity using a 3-dimensional 
displacement vector. 
 
  
